Oxford, United Kingdom
OMass Therapeutics, founded in 2016 and headquartered in the United Kingdom, stands at the forefront of pharmaceutical innovation, emphasizing its prowess in Life Sciences and Pharmaceutical industries. Harnessing high-resolution mass spectrometry, the company aims to address complex medical needs by discovering novel medicines.
The company's distinctive technology effectively targets complex structures like membrane receptors, catering specifically to severe unmet medical needs. By observing intact protein assemblies, OMass not only identifies drug leads that bind to target complexes but also ensures they perform functional roles in modulating complex formation.
Noteworthy support from prestigious investors such as Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, and British Patient Capital solidifies its market position. Its most recent £10.00M Series B investment secured on 15 May 2023 from British Patient Capital underscores investor confidence in its groundbreaking potential.
